For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh